NCT05865496View on ClinicalTrials.gov

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

July 31, 2024

Conditions
SinusitisNasal PolypsPolyps
Interventions
DRUG

611

611 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (4)

100005

Site 03, Beijing

100730

Site 01, Beijing

221004

Site 02, Xuzhou

430022

Site 04, Wuhan

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY